Results 31 to 40 of about 49,553 (292)
NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype
OncoImmunology, 2020 Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and remains associated with very poor survival. T cell infiltration into tumor tissue is associated with improved clinical outcome but little is known regarding the ...
Francesca Marcon +10 more
doaj +1 more source
Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells
Pharmaceutics, 2020 Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer death worldwide. Poor drug delivery to tumours is thought to limit chemotherapeutic treatment efficacy. Sonoporation combines ultrasound (US) and microbubbles to increase the permeability
Tormod Bjånes +8 more
doaj +1 more source
Targeting Pancreatic Ductal Adenocarcinoma (PDAC) [PDF]
Cellular Physiology and Biochemistry, 2020 Pancreatic cancers are among the most ominous, and among the most studied. Their complexities have provided ample material for a huge investigative effort, which is briefly surveyed in this review. Eradication by surgery has proven extremely difficult, and a successful chemotherapeutic approach is desperately needed.
Sofia Parrasia +6 more
openaire +5 more sources
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
PLoS ONE, 2021 Dysregulated expression of the secretory protein renalase can promote pancreatic ductal adenocarcinoma (PDAC) growth in animal models. We characterized renalase expression in premalignant and malignant PDAC tissue and investigated whether plasma renalase
Yasheen Gao +12 more
doaj +1 more source
New Biomarker Identified for PDAC [PDF]
Cancer Discovery, 2017 Abstract A new study suggests that the protein THBS2 could lead to early detection of pancreatic ductal adenocarcinoma. By testing for THBS2 and another marker, CA19-9, researchers identified blood samples from patients with the disease with 98% specificity and 87% sensitivity.
openaire +2 more sources
Open Medicine, 2023 Pancreatic cancer (PC) is an aggressive malignant disease. Pancreatic ductal adenocarcinoma (PDAC) is a main type of PDAC. The inhibition of aerobic glycolysis in PC cells is one of the approaches to treat PDAC.
Yin Wenke, Song Xiaoyan, Xiang Yue
doaj +1 more source
microRNAs: Novel regulators of the TGF-β pathway in pancreatic ductal adenocarcinoma
Molecular & Cellular Oncology, 2018 We identified that transforming growth factor-β (TGF-β) induces long non-coding RNA (lncRNA) MIR100HG along with its host microRNAs (miRNAs) miR-100 and miR-125b, to regulate its response in pancreatic ductal adenocarcinoma (PDAC).
Silvia Ottaviani, Leandro Castellano
doaj +1 more source
The Role of Autophagy in Pancreatic Cancer—Recent Advances
Biology, 2019 Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers with a 5-year survival rate of only 9%, despite ongoing efforts to improve treatment.
Maria New, Sharon Tooze
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer deeply affecting human health. Diagnosing early-stage PDAC is the key point to PDAC patients’ survival. However, the biomarkers for diagnosing early PDAC are inexact in most cases.
Zi-Mei Zhang +5 more
doaj +1 more source
Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents
Molecular & Cellular Oncology, 2018 We recently reported that bacteria can be found within pancreatic ductal adenocarcinoma (PDAC) tumors. Some of these bacteria can metabolize and thereby inactivate the nucleoside analog gemcitabine.
Leore T. Geller, Ravid Straussman
doaj +1 more source